Pfizer's maternal vaccine, sold as Abrysvo, and Sanofi and AstraZeneca's antibody shot, Beyfortus, are available in the ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

For a broader group of infants—0 to 7 months old—RSV-NET showed a 43 percent drop in hospitalizations in the 2024–2025 RSV season, and NVSN saw a 28 percent drop. Again, when Houston was excluded from ...

An aide to U.S. Health Secretary Robert F. Kennedy Jr. is seeking more information about three vaccines recommended by a ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).